Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Annals of Clinical and Laboratory Science|November 18, 2025
ABEI-Based Automated Immunoassays for PIVKA-II TestingDamien Gruson, Josipa RaguzFEBS Letters|September 21, 2007
Suppressor of T-cell receptor signalling 1 and 2 differentially regulate endocytosis and signalling of receptor tyrosine kinasesJosipa Raguz, Sebastian Wagner, Ivan Dikic, et al.Nature Communications|December 22, 2016
A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesisInes Jeric, Gabriele Maurer, Anna Lina Cavallo, et al.Oncoimmunology|June 10, 2025
Combining local cytokine delivery and systemic immunization with recombinant artLCMV boosts antitumor efficacy in several preclinical tumor modelsKimberly Pojar, Diana Reckendorfer, Judith Strauss, et al.Elife|July 20, 2016
Epidermal RAF prevents allergic skin diseaseJosipa Raguz, Ines Jeric, Theodora Niault, et al.Cancer Gene Therapy|April 28, 2026
Preclinical development of a mutant KRAS targeting therapeutic cancer vaccineCatarina Pinto, Romana Bischl, Lea Knezevic, et al.Frontiers in Oncology|November 1, 2021
Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector PlatformHenning Lauterbach, Sarah Schmidt, Kia Katchar, et al.Journal for Immunotherapy of Cancer|April 17, 2024
Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatmentJosipa Raguz, Catarina Pinto, Theresa Pölzlbauer, et al.Oncoimmunology|January 18, 2021
Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancerSarah Schmidt, Weldy V Bonilla, Andrea Reiter, et al.Cell Reports. Medicine|March 25, 2021
Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attackWeldy V Bonilla, Nicole Kirchhammer, Anna-Friederike Marx, et al.Pageof 1